He also identified the virus, which can cause infants to be born with severe physical and mental impairments as well as causing miscarriages and stillbirths.

Dr. Paul D. Parkman, whose research was instrumental in identifying the virus that causes rubella and developing a vaccine that has prevented an epidemic of the disease in the United States for more than 50 years, died on May 7 at his home in Auburn, N.Y., about 60 miles east of Rochester in the Finger Lakes region. He was 91.

The cause was lymphoblastic leukemia, his niece Theresa M. Leonardi said.

Rubella, also known as German measles because German scientists classified it in the 19th century, is a moderate illness for most patients, identified by a spotty and often itchy red rash. But in pregnancies, it can cause infants to be born with severe physical and mental impairments and can also cause miscarriages and stillbirths.

When Dr. Parkman was a pediatric medical resident in the 1950s at the State University Health Science Center (now the SUNY Upstate Medical University) in Syracuse, he once recalled, he anguished over a showing a new mother her stillborn baby whose rash, he would learn later, probably resulted from the mother’s infection with rubella during pregnancy.

In 1964 and 1965, rubella — an epidemic that struck every six to nine years — caused about 11,000 pregnancies to be miscarried, 2,100 newborns to die and 20,000 infants to be born with birth defects.

After the discovery of a vaccine for rubella, also known as German measles, displays educated the public about vaccination and the potential transmission of the virus from mother to fetus.Smith Collection/Gado, via Getty Images

That was the worst outbreak in three decades — and the last epidemic in the United States. The disease was declared eliminated in the Americas in 2015, although the virus has not yet been eradicated in Africa or Southeast Asia.

We are having trouble retrieving the article content.

Please enable JavaScript in your browser settings.


Thank you for your patience while we verify access. If you are in Reader mode please exit and log into your Times account, or subscribe for all of The Times.


Thank you for your patience while we verify access.

Already a subscriber? Log in.

Want all of The Times? Subscribe.